Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04906954

Combined Neuromuscular Electrical Stimulation and Nutritional Support for Advanced Gastrointestinal Cancer Patients.

Effects of Combining a Neuromuscular Electrical Stimulation Intervention With Nutritional Support in Deconditioned Patients With Advanced Gastrointestinal Cancer - DIG'ELECTROSTIM-01

Status
Withdrawn
Phase
N/A
Study type
Interventional
Enrollment
0 (actual)
Sponsor
GERCOR - Multidisciplinary Oncology Cooperative Group · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Dig' Electrostim-01 is phase II, single center (step 1) and multicentre (step 2), single-arm study to evaluate an 8-week NMES intervention combined with nutritional support in addition to usual patient care

Detailed description

Sarcopenia and cachexia are observed in more than 50% of patients with gastrointestinal (GI) cancer. Both negatively affect patient survival and health-related quality of life (HRQoL) due to decreased tolerance to anticancer treatments and increased susceptibility to infections and other complications. Therefore, sarcopenia and cachexia represent a major clinical issue in this setting. A multimodal therapeutic approach to the sarcopenia and cachexia management is recommended, including nutritional support and exercise with personalized oncology care and family-centered education. Neuromuscular electrical stimulation (NMES) generates muscle contractions using portable devices connected to surface electrodes. NMES is safe, does not require the active cooperation of the patient and can be self-administered at home, thereby providing an acceptable physical therapy for patients with advanced cancer and an altered Eastern Cooperative Oncology Group performance status (ECOG PS) and/or a high-symptom burden, for whom attendance to hospital-based exercise training is difficult. In this study, we hypothesize that NMES is a safe and effective physical-therapy strategy to improve HRQoL and to reduce cancer-induced sarcopenia in patients with metastatic GI cancer and altered ECOG PS (ECOG PS of 2).

Conditions

Interventions

TypeNameDescription
OTHERNMESStandardized strength program (75 Hz frequency, 40 cycles). The stimulation intensity will be increased up to the highest tolerated level in order to evoke strong muscle contractions.

Timeline

Start date
2023-09-01
Primary completion
2024-12-01
Completion
2024-12-01
First posted
2021-05-28
Last updated
2025-07-03

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04906954. Inclusion in this directory is not an endorsement.